No abstract available
MeSH terms
-
Cost-Benefit Analysis
-
Diabetic Ketoacidosis / drug therapy*
-
Diabetic Ketoacidosis / economics
-
Drug Monitoring
-
Hospital Charges / statistics & numerical data
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / economics
-
Infusions, Intravenous
-
Injections, Intravenous
-
Injections, Subcutaneous
-
Insulin / administration & dosage*
-
Insulin / economics
-
Intensive Care Units / economics
-
Intensive Care Units / statistics & numerical data*
-
Patient Selection
-
Safety
-
Treatment Outcome
Substances
-
Hypoglycemic Agents
-
Insulin